Stock listing
LPCN Stock Price, News, Filings & Events — Lipocine Inc.
Selected listing: LPCN · BOATS · USD · US
This page tracks Lipocine Inc.'s LPCN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LPCN:BOATS. LPCN:BOATS is the stock-level entry point for investors researching Lipocine Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Lipocine Inc. is a public company traded under the ticker LPCN in the American market. With a market capitalization of approximately $17.1 million, Lipocine focuses on developing innovative therapies for various medical conditions. The company is committed to advancing its product pipeline to address unmet medical needs.

- Ticker
- LPCN:BOATS
- Asset type
- Stock
- Market cap
- $18.7M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BOATS
- Currency
- USD
Lipocine Inc. LPCN:BOATS stock context
This page tracks Lipocine Inc.'s LPCN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following LPCN:BOATS. LPCN:BOATS is the stock-level entry point for investors researching Lipocine Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Lipocine Inc. is a public company traded under the ticker LPCN in the American market. With a market capitalization of approximately $17.1 million, Lipocine focuses on developing innovative therapies for various medical conditions. The company is committed to advancing its product pipeline to address unmet medical needs.
Latest news from Lipocine Inc.
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
September 14, 2026
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Lipocine : Appoints Michael J. Grissinger to Board of Directors
August 3, 2026
Lipocine Appoints Michael J. Grissinger to Board of Directors
August 3, 2026
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
June 4, 2026
Research Lipocine Inc.
Lipocine Inc. investor report
Review AI stock analysis and investor report context for LPCN:BOATS.
Lipocine Inc. company profile
View the public company page for Lipocine Inc. on 6ix.
Lipocine Inc. news
Read company news and market updates connected to Lipocine Inc..
Lipocine Inc. investor events
Find investor webinars, events, and replay context for Lipocine Inc..